Human Papillomavirus Infection
Symptoms, Doctors, Treatments, Advances & More

Save information for later
Sign Up

Learn About Human Papillomavirus Infection

What is the definition of Human Papillomavirus Infection?
Human papillomavirus (HPV) infection is a viral infection contracted through skin to skin contact. HPV is the most common type of sexually transmitted infection (STI). Over 100 different variations of HPV exist, and over 40 of them are transmitted through sexual contact with a person who has HPV. While many HPV infections are harmless, certain strains of the virus may cause genital warts or various cancers.
What are the symptoms of Human Papillomavirus Infection?
The most common symptom of a human papillomavirus infection is warts, particularly in the genital region. Other symptoms of a human papillomavirus infection include itching and redness on the skin surface.
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Human Papillomavirus Infection?
Many cases of HPV infections will go away on their own. Although there is no cure for HPV infections, complications can generally be treated. Genital warts can be treated with medication, or specific burning or freezing treatments to remove the growths.
Who are the top Human Papillomavirus Infection Local Doctors?
Elite in Human Papillomavirus Infection
Otolaryngology
Elite in Human Papillomavirus Infection
Otolaryngology

Johns Hopkins Health Care & Surgery Center - Green Spring Station, Lutherville

10803 Falls Road, Pavilion III STE 2300, Pavilion III STE 2300, 
Lutherville, MD 
Languages Spoken:
English, Arabic, French

Dr. Carole Fakhry is a head and neck surgical oncologist at Johns Hopkins and treats the breadth of patients with head and neck cancers, including cancers of the tonsils, base of tongue, mouth, larynx, thyroid, salivary gland (parotid, submandibular gland) and skin cancers among others. She is the Chief of the Division of Head and Neck Surgery and Director of the Head and Neck Cancer Center. She also serves as director of the head and neck group in the Bloomberg~Kimmel Institute for Cancer Immunotherapy and the head and neck surgical oncology fellowship. She is the associate editor for Oral Oncology and serves on several editorial boards. After an undergraduate degree at Stanford University, she completed medical school, residency in otolaryngology head and neck surgery, and a fellowship in head and neck surgical oncology at Johns Hopkins. She has also received a master’s in public health from the Johns Hopkins Bloomberg School of Public Health. She is presently a professor in the Johns Hopkins Department of Otolaryngology-Head and Neck Surgery, Oncology, and Johns Hopkins Bloomberg School of Public Health Department of Epidemiology. Her research interest focuses on the role of human papillomavirus (HPV) in head and neck squamous cell cancer. She has demonstrated that the presence of HPV confers a prognostic advantage to individuals with oropharyngeal cancer and that HPV is associated with unique clinical characteristics. In addition to the clinical implications of HPV in head and neck cancer, she is co-principal investigator of a large study to understand screening individuals at “high risk” of malignancy and evaluating imaging modalities to improve diagnostics and early detection of HPV- related head and neck cancer. Dr. Fakhry is rated as an Elite provider by MediFind in the treatment of Human Papillomavirus Infection. She is also highly rated in 12 other conditions, according to our data. Her clinical expertise encompasses Human Papillomavirus Infection, Head and Neck Squamous Cell Carcinoma (HNSCC), Salivary Gland Tumors, Laryngectomy, and Gastrostomy. Dr. Fakhry is board certified in Head And Neck Surgery.

Elite in Human Papillomavirus Infection
Otolaryngology
Elite in Human Papillomavirus Infection
Otolaryngology

Cleveland Clinic Main Campus

9500 Euclid Avenue, 
Cleveland, OH 
Experience:
32+ years
Languages Spoken:
English
Offers Telehealth

Joseph Scharpf is an Otolaryngologist practicing medicine in Cleveland, Ohio. He has been practicing medicine for over 32 years. Dr. Scharpf is rated as an Elite provider by MediFind in the treatment of Human Papillomavirus Infection. He is also highly rated in 30 other conditions, according to our data. His clinical expertise encompasses Laryngeal Cancer, Throat Cancer, Human Papillomavirus Infection, Thyroidectomy, and Laryngectomy. Dr. Scharpf is board certified in American Board Of Otolaryngology, 2005.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Human Papillomavirus Infection
Otolaryngology
Elite in Human Papillomavirus Infection
Otolaryngology

Cleveland Clinic Main Campus

10201 Carnegie Avenue, 
Cleveland, OH 
Experience:
24+ years
Languages Spoken:
English
Offers Telehealth

Shlomo Koyfman is an Otolaryngologist practicing medicine in Cleveland, Ohio. He has been practicing medicine for over 24 years. Dr. Koyfman is rated as an Elite provider by MediFind in the treatment of Human Papillomavirus Infection. He is also highly rated in 27 other conditions, according to our data. His clinical expertise encompasses Laryngeal Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), Throat Cancer, Laryngectomy, and Thyroidectomy. Dr. Koyfman is board certified in American Board Of Radiology, 2012.

What are the latest Human Papillomavirus Infection Clinical Trials?
STRatIfication of Vulvar Squamous Cell Carcinoma by HPV and p53 Status to Guide Excision

Summary: This study is being done to answer the following question: Are there types of early-stage vulvar cancer that require either less or more treatment than the usual approach?

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN)

Summary: The purpose of this study is to compare the efficacy and safety of ficlatuzumab plus cetuximab compared to placebo plus cetuximab in participants with recurrent/metastatic (R/M) HPV-negative Head and Neck Cancer. The primary hypothesis is that ficlatuzumab combined with cetuximab is superior to cetuximab alone in terms of progression-free survival and/or overall survival.